Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Core Viewpoint - Numinus Wellness Inc. reported significant growth in revenue for Q2 2025, driven by its focus on innovative mental health care and psychedelic-assisted therapies, although it also faced increased costs and operating losses [1][2]. Financial Performance - Total revenue for Q2 2025 reached CAD 1,512,435, marking an 83.8% increase from CAD 822,973 in Q2 2024 [2]. - Cost of revenue surged to CAD 1,007,691, a 175.7% increase from CAD 365,446 in the same quarter last year [2]. - Gross profit was CAD 504,744, reflecting a 10.3% increase from CAD 457,527 in Q2 2024, with a gross profit margin of 33.4%, down from 55.6% [2]. - Operating expenses rose to CAD 9,886,497, an 86.31% increase from CAD 5,306,523 in Q2 2024 [2]. - The company reported a comprehensive loss of CAD 7,705,397, compared to CAD 5,960,437 in the previous year [2]. Balance Sheet and Liquidity - Numinus ended the quarter with cash and cash equivalents amounting to CAD 705,631 [3]. Company Overview - Numinus Wellness Inc. is focused on developing and delivering innovative mental health care solutions, particularly through evidence-based psychedelic-assisted therapies, aiming to transform treatment for conditions like depression, anxiety, and substance use [4].